Stay updated on Nivolumab Ipilimumab in Mucinous Tumors Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Ipilimumab in Mucinous Tumors Clinical Trial page.

Latest updates to the Nivolumab Ipilimumab in Mucinous Tumors Clinical Trial page
- CheckyesterdayChange DetectedSite-wide government funding notice was added and the page revision tag updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check8 days agoChange DetectedMinor UI/metadata updates were implemented, such as Show glossary and revision/version label changes (v3.4.0; No FEAR Act Data; Last Update Submitted that Met QC Criteria), with core study content unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page now displays a new revision note 'Revision: v3.3.4' and the previous 'Revision: v3.3.3' note was removed.SummaryDifference0.1%

- Check43 days agoChange DetectedA new 'Locations' section is added with Pennsylvania listed as a site. The page footer shows revision v3.3.3, and the earlier 'Pennsylvania Locations' entry and 'HHS Vulnerability Disclosure' have been removed.SummaryDifference0.2%

- Check72 days agoChange DetectedRevision updated from v3.2.0 to v3.3.2 on the study page, with no observable changes to study content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check79 days agoChange DetectedRemoval of the funding status notice about government operating status and potential processing delays.SummaryDifference0.4%

Stay in the know with updates to Nivolumab Ipilimumab in Mucinous Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Ipilimumab in Mucinous Tumors Clinical Trial page.